A randomized, double-blind, two-treatment, single-period, single-dose, parallel design, comparative bioavailability study between RTPR- 021 (test adalimumab) 40 mg/0.8 ml prefilled syringe from Reliance Life Sciences Pvt. Ltd., India and Humira® (reference adalimumab) 40 mg/0.8 ml prefilled syringe from Abbott biotechnology Germany in healthy, adult, human subjects following subcutaneous administration under fasting condition.
Latest Information Update: 03 Jul 2019
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Reliance Life Sciences
- 30 Aug 2016 New trial record